About
Our Mission
Leadership
Partners
Our Technologies
TALEN® Technology
Gene Editing
PulseAgile Technology
Patents
Pipeline
Products
Clinical Indications
Manufacturing
Investors
Press Releases
Corporate presentation & ESG report
Scientific Presentations
Scientific Publications
Events and Webcasts
2021 Cellectis Innovation Days
Stock Information
Corporate Governance
Governance Documents
Board of Directors & Committee Members
Shareholders Meeting
SEC Filings
Contact
IR Inquiries
Email Alerts
Investor FAQ
Careers
Our Culture
Job Opportunities
Contact us
fr
Press Releases
Our latest news and press releases
Press releases
Corporate presentation
Scientific Presentations
Scientific Publications
Events and webcasts
Stock information
SEC filings
Financial Statements
Regulated information
Voting Rights & Share Capital
ATM Program
General meetings
Governance
The board and committee members
Corporate governance documents
FAQ
IR Inquiry
All
2024
2023
2022
2021
2020
2019
02
Dec 2019
16:30 E.S.T.
1st Patient Dosed with Cellectis’ Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Read more
20
Nov 2019
16:30 E.S.T.
Cellectis Wins Patent Challenge in Europe for a Method Using CRISPR-Cas9 for Gene Editing in T-Cells
Read more
13
Nov 2019
16:30 E.S.T.
Cellectis Publishes Creation of “Smart CAR T-Cells” for Potentially Safer, More Effective Treatments for Cancer in Nature Communications
Read more
06
Nov 2019
16:47 E.S.T.
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019
Read more
31
Oct 2019
16:30 E.S.T.
Cellectis to Hold Third Quarter and First Nine Months 2019 Earnings Call on Thursday, November 7, 2019 at 8:00 AM EST
Read more
30
Oct 2019
16:30 E.S.T.
The Institut Pasteur and Cellectis extend exclusive license rights by granting genOway the authority to take action against infringement
Read more
1
2
Next